R&D News | pharmaphorum

News

BioXcel shares rise on result of Alzheimer’s drug probe

Shares in BioXcel Therapeutics rose more than 31% in early trading today after the biotech said an independent audit of a phase 3 trial of its Alzheimer’s disease therapy

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

GSK targets younger age group with RSV jab Arexvy

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s

News

OrbiMed raises $4.3bn for latest biotech funds

International healthcare investment group OrbiMed has raised around $4.3 billion in committed financing for distribution across three new private funds that will be used t

News

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k

News

ESMO: Survival data mars Pluvicto prostate cancer trial

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistan

BioXcel shares rise on result of Alzheimer’s drug probe

ESMO: J&J’s Tagrisso challenge, and other highlights

GSK targets younger age group with RSV jab Arexvy

OrbiMed raises $4.3bn for latest biotech funds

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

ESMO: Survival data mars Pluvicto prostate cancer trial

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks